Investigating how to stabilize the Menin protein in acute myeloid leukemia
Official title: Targeting Menin Protein Stability In AML
Funded at Oregon Health & Science University · NIH-11212944 · Data updated 2026-11-12
This study is looking at a protein called Menin to see how it affects treatment for acute myeloid leukemia (AML), with the hope of finding better ways to help patients, especially those with certain genetic changes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | July 18, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 4R00CA279888-03 |
| Project ID | NIH-11212944 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, especially those with MLL1 rearrangements or other specific mutations.
✕Less likely to help
Patients with non-hematological cancers or those without acute myeloid leukemia may not receive any benefit from this research.
What this research studies
This research focuses on understanding the role of the Menin protein in acute myeloid leukemia (AML) and how its stability affects treatment outcomes. By exploring the interactions between Menin and other proteins, the study aims to identify ways to enhance the effectiveness of small molecule inhibitors that target Menin. Patients may benefit from insights that could lead to improved therapies for aggressive forms of leukemia, particularly those with specific genetic mutations. The research employs laboratory experiments to analyze protein interactions and stability in AML cells.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia by targeting the Menin protein.
How similar studies have gone: Previous clinical trials using small molecule MENIN inhibitors have shown early success, indicating that this approach has potential based on prior research.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Cutler, Jevon — Oregon Health & Science University
- Study coordinator: Cutler, Jevon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.